Hu TH#, Luh DL#, Tsao YY, Lin TY, Chang CJ, Su WW, Yang CC, Yang CJ, Chen HP, Liao PY, Su SL, Chen LS, Hsiu-Hsi Chen T, Yeh YP*; Changhua Hepatitis C Elimination Task Force. Using the Diabetes Care System for a County-Wide Hepatitis C Elimination: An Integrated Community-Based Shared Care Model in Taiwan. Am J Gastroenterol. 2024 May 1;119(5):883-892. (SCI)
Hu TH#, Wu JC#, Huang ST, Chu TH, Han AJ, Shih TW, Chang YC, Yang SM, Ko CY, Lin YW, Kung ML*, Tai MH*. HDGF stimulates liver tumorigenesis by enhancing reactive oxygen species generation in mitochondria. J Biol Chem. 2023 Oct 10;299(11):105335. (SCI)
Yang SY#, Hu TH#, Chou YP, Kuo YH, Tsai MC, Chang KC, Yen YH, Tseng PL*. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation. J Infect Public Health. 2023 Nov;16(11):1852-1859. (SCI)
Hu TH, Luh DL, Tsao YY, Chen LS, Chen HH, Yeh YP.* Enhancing testing and treatment uptake of HCV cascade care for the diabetes population via an integrated community-based shared care model. J Infect. 2023 Aug;87(2):151-152. (Letter to the Editor) (SCI)
Su WW#, Yang CC#, Chang RW, Yeh YH, Yen HH, Yang CC, Lee YL, Liu CE, Liang SY, Sung ML, Ko SY, Kuo CY, Chen SL, Yeh YP*, Hu TH*; Changhua Hepatitis C Elimination Task Force. A new collaborative care approach toward hepatitis C elimination in marginalized populations. J Infect Public Health. 2023 May 19;16(8):1201-1208. (SCI)
Tsai MC, Yong CC, Lin CC, Lee WC, Wang CC, Hung CH, Chen IH, Cheng YF, Hsiao CC*, Hu TH*, Chen CL. Living donor liver transplantation for Barcelona clinic liver cancer (BCLC) intermediate-stage hepatocellular carcinoma. HepatoBiliary Surg Nutr. 2023 Apr;12(2):169-182. (SCI)
Chang KC, Lin MT, Wang JH, Hung CH, Chen CH, Chiu SY*, Hu TH*. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral. Viruses. 2022 Nov 29;14(12):2671. (SCI)
Chu TH#, Ko CY#, Tai PH, Chang YC, Huang CC, Wu TY, Chan HH, Wu PH, Weng CH, Lin YW, Kung ML, Fang CC, Wu JC, Wen ZH, Lee YK, Hu TH*, Tai MH*. Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma. J Biol Chem. 2022 Oct;298(10):102442. (SCI)
Lin MT, Chiu YH, Chang KC, Li WF, Yong CC, Liu YW , Wang JH, Kuo FY, Huang CC, Wang CC, Hsiao CC*, Hu TH*. Significant association between serum Wisteria floribunda agglutinin-positive Mac-2-binding protein and prognosis of hepatocellular carcinoma after surgical treatment. Am J Cancer Res. 2022 Feb 15;12(2):601-614. (SCI)
Wu CK, Chen LW, Chang TS, Tung SY, Lin CY, Hung CH, Lu SN, Lin CL, Chen CH, Hsu CW*, Hu TH*, Sheen IS. The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir. Viruses. 2022 Feb;14(2):362. (SCI)
Tsai MC, Wang CC, Lee WC, Lin CC, Chang KC, Chen CH, Hung CH, Lin MT, Hsiao CC, Chen CL, Chien RN, Hu TH*. Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection. Liver Cancer. 2022 Jan;11:22–37. (SCI)
Tsai MC, Hung CH, Lu SN, Wang JH, Chen CH, Kee KM, Chang KC, Chao TL, Hu TH*. The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan. Biomed J. 2021 Dec;44(6S1):S126-S131. (SCI)
Hu TH(co-first), Su WW(co-first), Yang CC, Yang CC, Kuo WH, Chen YY, Yeh YH, Chen SS, Tsao YY, Chen KM, Yan SL, Lai JH, Yao CD, Lim CH, Jen HH, Yeh YP*, Chen SL, Chen HH, Chen SC; Changhua Hepatitis C Elimination Task Force. Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan. Am J Kidney Dis. 2021 Oct;78(4):511-519.e1. (SCI)
Chuang WL, Hu TH*, Buggisch P, Moreno C, Su WW, Biancone L, Camargo M, Hyland R, Lu S, Kirby BJ, Dvory-Sobol H, Osinusi A, Gaggar A, Peng CY, Liu CH, Sise ME, Mangia A. Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease. Am J Gastroenterol. 2021 Sep 1;116(9):1924-1928. (SCI)
Huang PY, Wang JH, Hung CH, Lu SN, Hu TH*, Chen CH*. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients. J Viral Hepat. 2021 Aug;28(8):1141-1149. (SCI)
Huang PY, Chiu YH, Chang KC, Tseng PL, Yen YH, Tsai MC, Wang JH, Kee KM, Chen CH, Hung CH, Chiu KW, Hu TH*. A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir. Hepatol Int. 2021 Apr;15(2):310-317. (SCI)
Huang TH#, Lin MT#, Wang JH, Chang KC, Yen YH, Kuo FY, Huang CC, Hsiao CC, Chiu SY, Lu SN, Wang CC, Hu TH＊. Clinical and novel application of FibroScan, FIB-4 and aspartate aminotransferase-to-platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction. Int J Clin Pract. 2021 Apr;75(4):e13945. (SCI)
Kuo YH , Wang JH, Hung CH, Lu SN, Hu TH*,Chen CH*.Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatol Int. 2021 Apr;15(2):301-309. (SCI)
Huang CY#, Chung CL#, Hu TH#, Chen JJ, Liu PF, Chen CL*. Recent progress in TGF-β inhibitors for cancer therapy.
Biomed Pharmacother. 2021 Feb;134:111046. (SCI) Review
Tsai MC, Chang KC, Yen YH, Wu CK, Lin MT, Hu TH*.Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):208-213. (SCI)
Lin MT, Chang KC, Yen YH, Tsai MC, Chen CH, Wang JH, Hsiao CC, Chiu YH, Hu TH*. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. J Formos Med Assoc. 2021 Jan;120(1 Pt 3):621-628. (SCI)
Hu TH, Chiu YH, Tseng PL, Chen CH, Lu SN, Wang JH, Hung CH, Kee KM, Lin MT, Chang KC*, Lin MC, Chien RN*. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naive patients with chronic hepatitis B-related compensated cirrhosis in Taiwan. Aliment Pharmacol Ther. 2020 Dec;52(11-12):1695-1706. (SCI)
Chiu SM, Tsai MC, Lin CY*, Chen CH, Lu SN, Hung CH, Sheen IS, Chien RN, Lin CL, Hu TH*, Cheng YF, Chen CL. Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment. PLoS One. 2020 Apr 14;15(4):e0231102. (SCI)
Tsai MC, Huang CC, Wei YC, Liu TT, Lin MT, Yi LN, Lin PR, Wang CC, Chu TH, Hsiao CC, Hu TH*, Tai MH*. Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma. Int J Mol Sci. 2020 Mar 17;21(6):2060. (SCI)
Yen YH, Cheng YF, Wang JH, Lin CC, Chen YY, Yong CC, Liu YW, Cheng JY, Chen CH, Hu TH*. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. PLoS One. 2020 Mar 12;15(3):e0230005. (SCI)
Tsai MC, Yen YH, Chang KC, Hung CH, Chen CH, Lin MT, Hu TH*. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection. BMC Cancer. 2019 Dec 2;19(1):1169. (SCI)
Tsai MC#, Lin CY#, Hung CH, Lu SN, Tung SY, Chien RN, Lin CL, Wang JH, Chen CH, Chang KC, Hu TH*, Sheen IS*. Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience. J Viral Hepat. 2019 Dec;26(12):1404-1412. (SCI)
Yen YH, Chen CH, Hung CH, Wang JH, Lu SN, Kee KM, Hu TH*. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data. PLoS One. 2019 Oct 3;14(10):e0222605. (SCI)
Yen YH, Kuo FY, Chen CH, Hu TH*, Lu SN, Wang JH, Hung CH. Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice. Medicine (Baltimore). 2019 Jul;98(27):e16270. (SCI)
Sou FM, Wu CK, Chang KC, Lu SN, Wang JH, Hung CH, Chen CH, Kee KM, Yen YH, Lin MT, Tsai MC, Hu TH*. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. J Formos Med Assoc. 2019 Jan;118(1 Pt 3):504-513. (SCI)
Yen YH, Hu TH*. Reply to the Letter to the Editor regarding Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease: More questions than answer? J Formos Med Assoc. 2019 Jan;118(1 Pt 3):537-538. (SCI)
Yen YH, Kee KM, Chen CH, Hu TH*, Lu SN, Wang JH, Hung CH. Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. PLoS One. 2019 Jan 9;14(1):e0208858. (SCI)
Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. Dig Liver Dis. 2019 Jan;51(1):142-148. (SCI)
Yen YH, Kuo FY, Lin CC, Chen CL, Chang KC, Tsai MC, Hu TH*. Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter. Transplant Proc. 2018 Dec;50(10):3533-3538. (SCI)
Yen YH, Kee KM, Kuo FY, Chang KC, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort. Medicine (Baltimore). 2018 Dec;97(50):e13383. (SCI)
Yen YH, Tsai MC, Wu CK, Chang KC, Hung CH, Chiu KW, Lu SN, Wang JH, Chen CH, Kee KM, Kuo YH, Tseng PL, Lin MT, Huang CM, Lin JT, Hu TH*. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study. J Formos Med Assoc. 2018 Sep;117(9):833-840. (SCI)
Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS One. 2018 Jun 28;13(6):e0199760. doi: 10.1371/journal.pone.0199760.
Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, Wu CK, Lin JT, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. Liver Int. 2018 Jun;38(6):1064-1073. (SCI)
Chen CH, Hsu YC, Lu SN, Hung CH, Wang JH, Lee CM, u TH*. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J Viral Hepat. 2018 May;25(5):590-597. (SCI)
Yen YH, Hu TH*. Reply to the letters to the editor regarding the elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease: Methodological issues. J Formos Med Assoc. 2018 Apr;117(4):352.
Yen YH, Chang KC, Tsai MC, Tseng PL, Lin MT, Wu CK, Lin JT, Hu TH*, Wang JH, Chen CH. Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. J Formos Med Assoc. 2018 Apr;117(4):268-275.
Yen YH, Chen JF, Wu CK, Lin MT, Chang KC, Tseng PL, Tsai MC, Lin JT, Hu TH*. The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice. J Formos Med Assoc. 2017 Nov;116(11):852-861. (SCI)
Yen YH, Chen JB*, Cheng BC, Chen JF, Chang KC, Tseng PL, Wu CK, Tsai MC, Lin MT, Hu TH*. Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study. PLoS One. 2017 Apr 20;12(4):e0176027. (SCI)
Cheng BC#, Yen YH#(co-first), Chen JF, Wu CK, Chang KC, Tseng PL, Tsai MC, Lin MT, Lin JT, Chen JB*, Hu TH*. Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population. Sci Rep. 2017 Apr 19;7:46458. (SCI)
Lin MT, Wang CC, Cheng YF, Eng HL, Yen YH, Tsai MC, Tseng PL, Chang KC, Wu CK, Hu TH*. Comprehensive Comparison of Multiple-Detector Computed Tomography and Dynamic Magnetic Resonance Imaging in the Diagnosis of Hepatocellular Carcinoma with Varying Degrees of Fibrosis. PLoS One. 2016 Nov 9;11(11):e0166157. (SCI)
Lin MT, Yen YH, Tsai MC, Tseng PL, Chang KC, Wu CK, Hu TH*. Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice. PLoS One. 2016 Nov 2;11(11):e0165416. (SCI)
Yen YH, Huang CM, Wei KL, Wang JH, Lu SN, Lee CM, Hung CH, Chen CH, Tseng PL, Chang KC, Tsai MC, Lin MT, Wu CK, Yang CH, Moi SH, Cho CL, Hu TH*. MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. Sci Rep. 2016 Sep 26;6:33816. (SCI)
Wang HM, Hung CH, Lee CM, Lu SN, Wang JH, Yen YH, Kee KM, Chang KC, Tseng PL, Hu TH*, Chen CH*. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naive and -experienced chronic hepatitis B patients. J Gastroenterol Hepatol. 2016 Jul;31(7):1307-14. (SCI)
Wu CK, Chang KC, Hung CH, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hu TH*. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. J Antimicrob Chemother. 2016 Jul;71(7):1943-7. (SCI)
Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Chang KC, Yen YH, Lin MT, Hu TH*. Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study. PLoS One. 2016 Mar 10;11(3):e0149761. (SCI)
Wu CK, Chang KC, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Lin MT, Yen YH, Hung CH, Hu TH*. Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase Levels. PLoS One. 2016 Mar 11;11(3):e0142378. (SCI)
Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH*. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016 Jan;22(1):95.e1-7. (SCI)
Chen SC, Hu TH(co-first), Huang CC, Kung ML, Chu TH, Yi LN, Huang ST, Chan HH, Chuang JH, Liu LF, Wu HC, Wu DC, Chang MC*, Tai MH*. Hepatoma-derived growth factor/nucleolin axis as a novel oncogenic pathway in liver carcinogenesis. Oncotarget. 2015 Jun 30;6(18):16253-70. (SCI)
Chang KC, Tseng PL, Wu YY, Hung CH, Huang CM, Lu SN, Wang JH, Lee CM, Chen CH, Tsai MC, Yen YH, Lin MT, Wu CK, Huang CC, Chen HH, Hu TH*. A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2015 May;13(5):1017-24. (SCI)
Lin MT, Chang KC, Chou YP, Tseng PL, Yen YH, Wang CC, Tsai MC, Cheng YF, Eng HL, Wu CK, Hu TH*. The validation of the 2010 American Association for the Study of Liver Diseases guideline for the diagnosis of hepatocellular carcinoma in an endemic area. J Gastroenterol Hepatol. 2015 Feb;30(2):345-51. (SCI)
Hu TH, Chen CL*, Lin CC, Wang CC, Chiu KW, Yong CC, Liu YW, Eng HL. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. Transplantation. 2014 Apr 27;97 Suppl 8:S53-9. (SCI)
Tsai MC, Yu HC(co-first), Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH*, Hu TH*. Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis. J Gastroenterol Hepatol. 2014 Mar;29(3):568-75. (SCI)
Tsai MC, Chen CH*, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH*. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014 Feb;20(2):O90-O100. (SCI)
Lin MT, Chou YP, Hu TH*, Yu HC, Hsu YC, Tsai MC, Tseng PL, Chang KC, Yen YH, Chiu KW*. Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections. Arch Virol. 2014 Jan;159(1):29-37. (SCI)
Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH*. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer. 2013 Oct 29;109(9):2481-8. (SCI)
Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH*.(Correspondence*). Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts. Am J Kidney Dis. 2013 Oct;62(4):789-95. (SCI)
Hung CH, Chang KC, Lu SN, Wang JH, Chen CH, Lee CM, Hu TH*. Spontaneous clearance of hepatitis C virus in an interleukin 28B favorable genotype highly prevalent area. Hepatology. 2013 May;57(5):2089-90. (SCI)
Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, Yen MF, Lin SC, Yen YH, Tsai MC, Tseng PL, Hu TH* (correspondence*). A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother. 2012 Nov;67(11):2766-72. (SCI)
Chiu KW*, Tsai MC, Wu KL, Chiu YC, Lin MT, Hu TH* (correspondence*). Surveillance cultures of samples obtained from biopsy channels and automated endoscope reprocessors after high-level disinfection of gastrointestinal endoscopes.BMC Gastroenterol. 2012 Sep 3;12:120. (SCI)
Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN, Yen YH, Hu TH* (correspondence*). A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. J Antimicrob Chemother. 2012 Mar;67(3):696-9. (SCI)
Chiu KW, Lu LS, Wu KL, Lin MT, Hu ML, Tai WC, Chiu YC, Chuah SK, Hu TH * (correspondence*). Surveillance culture monitoring of double-balloon enteroscopy reprocessing with high-level disinfection. Eur J Clin Invest. 2012 Apr;42(4):427-31. (SCI)
Hu TH*(correspondence*), Tsai MC, Chien YS, Chen YT, Chen TC, Lin MT, Chang KC, Chiu KW. A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients. Antivir Ther. 2012 April; 17(4):745-53. (SCI)
Hu TH* (correspondence*), Tsai MC, Chen YT, Chien YS, Hung CH, Chen TC, Tseng PL, Chang KC, Yen YH. The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up. Hepatol Int. 2012 April 2012;6(2):449-456. (SCI)
Hu TH* (correspondence*), Chuah SK, Hsu PI, Wu DC, Tai WC, Chiu YC, Wu KL, Kuo CM, Hu ML. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori. Am J Med Sci. 2011 Sep;342(3):177-81. (SCI)
Lin MT, Chen CL, Wang CC, Cheng YF, Eng HL, Wang JH, Chiu KW, Lee CM, Hu TH* (correspondence*). Diagnostic sensitivity of hepatocellular carcinoma imaging and its application to non-cirrhotic patients. J Gastroenterol Hepatol. 2011 Apr;26(4):745-50. (SCI)
Tsai MC, Chen YT, Chien YS, Chen TC, Hu TH* (correspondence*). Hepatitis B virus infection and renal transplantation. World J Gastroenterol. 2010 Aug 21;16(31):3878-87. Review. (SCI)
Tsai MC, Chen CH, Lee CM, Chen YT, Chien YS, Hung CH, Wang JH, Lu SN, Yen YH, Changchien CS, Hu TH* (correspondence*). The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. J Hepatol. 2009 Feb;50(2):281-8. (SCI)
Hu TH, Lin JW, Chen HH, Liu LF, Chuah SK, Tai MH*. The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis Colon Rectum. 2009 Feb;52(2):319-26. (SCI)
Tai WC, Chuah SK, Lin JW, Chen HH, Huang HY, Kuo CM, Yi LN, Lee CM, Changchien CS, Hu TH* (correspondence*). Colorectal mesenchymal tumors - from smooth muscle tumors to stromal tumors. Oncol Rep. 2008 Nov;20(5):1157-64. (SCI)
Tsai MC, Lin JW, Lin SE, Chen HH, Lee CM, Hu TH* (correspondence*). Prognostic analysis of rectal stromal tumors by reference of National Institutes of Health risk categories and immunohistochemical studies. Dis Colon Rectum. 2008 Oct;51(10):1535-43. (SCI)
Tseng PL, Tai MH, Huang CC, Wang CC, Lin JW, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, Changchien CS, Hu TH* (correspondence*). Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol. 2008 Oct 1;98(5):349-57. (SCI)
Hu TH, Tai MH, Chuah SK, Chen HH, Lin JW, Huang HY, Chou YP, Yi LN, Kuo CM, Changchien CS*. Elevated p21 expression is associated with poor prognosis of rectal stromal tumors after resection. J Surg Oncol. 2008 Aug 1;98(2):117-23.(SCI)
Chou YP, Lin JW, Wang CC, Chiu YC, Huang CC, Chuah SK, Tai MH, Yi LN, Lee CM, Changchien CS, Hu TH* (correspondence*). The abnormalities in the p53/p21WAF1 pathway have a significant role in the pathogenesis and progression of gastrointestinal stromal tumors. Oncol Rep. 2008 Jan;19(1):49-56.(SCI)
